Skip to Content
Cancer Imaging Program (CIP)
Contact CIP
Show menu
Search this site
Last Updated: 10/28/16

Imaging Response Criteria

Response Evaluation Criteria in Solid Tumors (RECIST) — The current de facto standard for measuring response by imaging in oncology clinical trials, RECIST primarily uses anatomic change in lesion size for determining response to treatment. RECIST was developed by an expert panel of international experts and is validated using data from tens of thousands of cases.

Imaging-based response criteria for [18F]FDG-PET scans:

Imaging-based response criteria for brain tumor imaging:

  • McDonald Criteria — published in 1990 for use with contrast-enhanced CT and MRI scans of the head, response under the McDonald Criteria is based on changes in tumor size and interpreted in light of steroid use and neurologic findings
  • Response Assessment in Neuro-Oncology (RANO): published in 2010, RANO is an update to the McDonald Criteria which also takes into consideration non-contrast enhancing components of the tumor and CT/MRI scans seen on the T2-weighted and FLAIR sequences.
  • RANO — Brain Metastases: published in 2015, RANO-BM was developed by the RANO-BM Working Group as a standard response and progression criteria for use in clinical trials dealing with metastatic lesions to the brain

Imaging-based response criteria for lymphoma:

  • International Working Group (Cheson) Criteria: published in 2007, the Cheson criteria defines standardized response criteria for Hodgkin’s and non-Hodgkin’s lymphoma using [18F]FDG PET, immunohistochemistry, and flow cytometry.
  • Deauville Criteria: published in 2009, the Deauville Criteria describes a simplified 5 point scale to standardize interpretation of [18F]FDG PET scans in the setting of lymphoma
  • Lugano Recommendations: published in 2014 as a result of a workshop at the 12th International Conference on Malignant Lymphoma, the Lugano Recommendations represent a set of revised recommendations regarding the use of the Cheson and Deauville Criteria and formally incorporated [18F]FDG PET into standard staging and response evaluation for FDG-avid lymphomas.

Imaging-based response criteria for bone lesions:

Other imaging-based response criteria: